ABB
S01E113 : MULTIPOLAR SUPPLY 1/1 : ABB
16 October 2026: ABB sells off its robotics future to SoftBank to fund a localized electrification grift. Peeling back the drywall on the corporate bait-and-switch funding the grid.
Theme: Multipolar Supply
SUPPLY LENS: "China Plus One" strategy, reshoring CAPEX, and tech localization ROI.
Apple Supply Chain
S01E110 : MULTIPOLAR SUPPLY 2/3 : INTEL / SAMSUNG
14 October 2026: The geopolitical panic room opens in Cupertino. As Apple attempts to untangle its absolute reliance on TSMC, we examine the billion-dollar gamble on Intel and Samsung's secondary foundries.
Intel 18A
NOTES: Intel / Samsung: The Multi-Billion Dollar Silicon Fleecing
The multipolar supply narrative is a taxpayer-funded mirage. Intel and Samsung are bleeding billions in foundry losses while failing to match TSMC's manufacturing scale and silicon yields.
Intel
AUDIT: Intel / Samsung: Silicon’s Multipolar Mirage
A forensic audit of the China Plus One strategy reveals the operational friction and capital expenditure required as Intel and Samsung attempt to establish a multipolar semiconductor supply chain.
Foxconn / TSMC
S01E107 : MULTIPOLAR SUPPLY 1/1 : FOXCONN / TSMC
File open 12 October 2026: Foxconn / TSMC / Multipolar Supply.
Foxconn / TSMC
NOTES: Foxconn / TSMC: The $165 Billion Helium Grift
Marcus on Foxconn / TSMC: the spin vs the invoice.
Foxconn / TSMC
AUDIT: Foxconn / TSMC: The Helium Bottleneck in Multipolar Silicon
Forensic audit of Foxconn / TSMC under Multipolar Supply.
ABB
NOTES: Abbott: Abbott's Electronic Apothecary is a Flesh Trap
The dark reality of the electronic apothecary. When chronic pain management becomes a proprietary biological lease, patients are trapped by catastrophic battery drains, mandatory surgical revisions, and dangerous MRI bottlenecks.
ABB
AUDIT: Abbott: The Electronic Apothecary: Anatomy of a Neuromodulation Trap
An analytical review of Abbott's Proclaim neuromodulation system, examining the clinical paradigm shift from pharmacological pain management to structural Dorsal Root Ganglion stimulation and its impact on healthcare economics.